Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Nestlé recalls infant formula in 49 countries. See list. - 2The most effective method to Recuperate After a Dental Embed Strategy: A Far reaching Guide
- 3New findings suggest atmosphere could exist on exoplanet TOI-561b
- 4Ukraine apologizes to Finland for crashed drones
- 5Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- Surge of off‑lease electric vehicles expected to drive down used EV prices
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- Holiday season sees uptick in norovirus cases, according to CDC
- Civil rights leader Jesse Jackson hospitalized, family requests prayers
- Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion
- SpaceX launches Starlink missions in dual-coast spaceflight doubleheader (videos)
- This Week In Space podcast: Episode 189 — Privatizing Orbit
- Vote in favor of Your Number one kind of pie
